World Health Organization Raises Alert Over Critical Lack of Obesity Jabs
Less than one in 10 people eligible to benefit from obesity jabs such as Wegovy have access to them, warns the World Health Organization as it issues its first advice on the therapies.
Considering more than one billion people worldwide now obese, it is advocating for increased and just access to this class of drugs.
Per estimates, in excess of 2,000,000,000 are projected to be obese by 2030 if no action is taken.
"The latest guidelines acknowledges that excess weight is a long-term condition that can be treated with thorough and lifelong treatment," remarked its chief Tedros Adhanom Ghebreyesus.
High costs, constrained manufacturing, and distribution challenges are significant obstacles to widespread access to the jabs that can assist patients in reducing substantial weight, explains the agency.
Skinny Jab Shortage
Despite the present best projected scenario, the production of GLP-1 therapies might only reach around 100 million people – under 10% of the global need, as stated by the WHO.
The recommendation encourages governments and firms to widen access, by measures such as patent sharing.
The intellectual property rights on a key compound – the core component of Novo Nordisk's Wegovy – is scheduled to end in a number of countries in 2026.
How Obesity Drugs Operate
These medications replicate a biological compound to delay gastric emptying, curb appetite and increase the sense of being full so users consume fewer calories.
Individuals usually see weight reduction after several weeks of commencing the once-weekly jabs.
Studies indicates patients may put most of the weight back on within a year of halting the drug, when their normal food cravings come back.
To be carrying excess weight elevates your chance for experiencing diseases, including diabetes, heart disease, brain attack, and certain cancers.
Excess weight impacts people in all nations and was associated with millions of deaths worldwide in 2024, as per the health agency.
